{"organizations": [], "uuid": "c9bab20e4d4de6ab328d8f209daf95856562f3db", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180129.html", "section_title": "Archive News &amp; Video for Monday, 29 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-sumitomo-dainippon-pharma-unit-say/brief-sumitomo-dainippon-pharma-unit-says-positive-topline-results-from-study-of-apomorphine-sublingual-film-idUSL4N1PP1HA", "country": "US", "domain_rank": 408, "title": "BRIEF-Sumitomo Dainippon Pharma unit says positive topline results from study of apomorphine sublingual film", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.901, "site_type": "news", "published": "2018-01-30T10:17:00.000+02:00", "replies_count": 0, "uuid": "c9bab20e4d4de6ab328d8f209daf95856562f3db"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-sumitomo-dainippon-pharma-unit-say/brief-sumitomo-dainippon-pharma-unit-says-positive-topline-results-from-study-of-apomorphine-sublingual-film-idUSL4N1PP1HA", "ord_in_thread": 0, "title": "BRIEF-Sumitomo Dainippon Pharma unit says positive topline results from study of apomorphine sublingual film", "locations": [], "entities": {"persons": [{"name": "sunov", "sentiment": "negative"}, {"name": "parkinson", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "sumitomo dainippon pharma co ltd", "sentiment": "negative"}, {"name": "brief-sumitomo dainippon pharma", "sentiment": "negative"}, {"name": "sunovion pharmaceuticals inc.", "sentiment": "negative"}, {"name": "beijing headline news", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 30 (Reuters) - Sumitomo Dainippon Pharma Co Ltd\n* Says unit Sunovion Pharmaceuticals Inc. (Sunovion) announced topline results from its pivotal Phase 3, randomized, double-blind, placebo-controlled clinical trial, CTH-300, that evaluated apomorphine sublingual film (APL-130277) in patients with Parkinsonâ€™s disease (PD) who experience motor fluctuations (OFF episodes)\n* Study CTH-300 met its primary and key secondary endpoints, and the medicine was also generally well-tolerated by study participants\nSource text in Japanese: goo.gl/sE7Qks\nFurther company coverage: (Beijing Headline News)\n ", "external_links": ["https://goo.gl/sE7Qks", "http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-30T10:17:00.000+02:00", "crawled": "2018-01-30T18:43:01.001+02:00", "highlightTitle": ""}